-
Barco joins Chelsea rebuild from Strasbourg
-
Wimbledon champ Noskova ready for 'new opportunity'
-
Commonwealth Games faces uncertain future ahead of centenary edition
-
Japan's Kuwaki wins women's British Open to clinch first major title
-
Moroccans gather at Ceuta border, desperate for news of loved ones
-
Sabalenka aims to bounce back in Toronto after Wimbledon disappointment
-
Finucane seals fourth cycling gold on final day of Commonwealth Games
-
Iran says close to Hormuz deal with Oman, after US suspends attack plan
-
At Nepal school, outpouring of grief for climber Nirmal Purja
-
'Spider-Man' soars to huge $355 million opening in North America
-
Tourists slowly return to French bay opposite huge wildfire
-
Handbag tosses and high-heeled sprints: Amsterdam celebrates Drag Olympics
-
Helicopter crew killed in Greece fires
-
Trump's on-again-off-again war against Iran: in his own words
-
Wiebes takes dominant second win at Tour de France Femmes
-
Dodgers land Tigers pitching ace Skubal in MLB trade deadline blockbuster
-
Suicide attack kills 13 during protest in northern Pakistan: police
-
Infantino struggling to survive, says former IOC marketing chief
-
Helicopters collide in Greece as fires spread
-
OPEC+ boosts September production by 188,000 barrels/day
-
Power returns to Cuba's west after grid failure
-
Rescuers recover climber Nirmal Purja's body after avalanche disaster
-
At least 72 died in Spain's Ceuta migrant rush
-
Fire toll mounts in Greece as blazes spread
-
South Korea records its highest-ever temperature of 42.5C
-
Sri Lanka deploys troops after prison riot
-
Trump says US, Israel to hold off on Iran strikes
-
Baltics transform from Soviet stagnation to startup hubs
-
Messi returns as Inter Miami draw 2-2 against Columbus Crew
-
AI keeps consumer prices high in 'RAMaggedon' chip crunch
-
Five of Cuba's 15 provinces without power as grid fails again
-
Dressel, Walsh win 50m free titles at US Swimming Championships
-
Baltic startups take aim at deterring Russia on NATO's eastern flank
-
OPEC+ tipped to raise production again but new quotas loom
-
Tourists chase high-octane thrill in China's trending biker capital
-
De Zerbi unsure over Richarlison's future at Spurs
-
Vincent Pastore, who played 'Big Pussy' on 'The Sopranos,' dead at 80
-
Tottenham manager De Zerbi 'happy' with pre-season progress
-
Lula, Brazil's political titan, races against time
-
Brazil's Lula launches fourth term bid as Trump looms over campaign
-
When rogue AI launches a cyberattack, who is legally responsible?
-
Alonso welcomes Mudryk's Chelsea return after doping ban
-
Venezuela transition talks to start in person next week: govt
-
'Damn hot': Last summer for Japan cosplay extravaganza
-
Colombia truck bomb wounds 14 ahead of presidential inauguration
-
Auger-Aliassime playing for hometown pride at Montreal Masters
-
Eala stuns Osaka to book Washington final against Pegula
-
Commonwealth Games poster boy Kerr delivers mile gold in Glasgow
-
13 dead after small tourist plane crashes in Peru
-
Pegula defeats Shnaider to reach Washington Open final
'We have always won': Ebola pioneer still on front line at 84
In 1976, young Congolese doctor Jean-Jacques Muyembe was sent to a remote village to look into a mysterious illness and found himself confronting Ebola, a deadly virus the world did not yet know.
Just back in the Democratic Republic of Congo after studying in Belgium, he had been called to Yambuku where doctors initially thought they were dealing with typhoid or yellow fever.
He drew blood from a sick nun and sent the sample to Belgium where microbiologist Peter Piot would soon isolate the new virus, later named Ebola after a nearby river.
At the time, Muyembe had little sense of the danger he had exposed himself to.
"When I removed the needle, the blood kept flowing and my fingers were covered in it," he told AFP in Kinshasa.
"We had no gloves, no gowns, no masks as we do today."
Fifty years later, and now aged 84, Muyembe is still on the front line against a virus he helped uncover as the DRC battles its 17th deadly outbreak.
Despite the scale of the crisis, with 808 people infected and 192 killed in the country, according to the World Health Organization, he stressed: "We have always won the battle against Ebola."
- Animals to humans -
The latest outbreak, declared on May 15, has mainly hit the remote, conflict-weary northeastern Ituri province.
Causing it is the Bundibugyo strain, for which there is currently no vaccine or treatment, unlike the more common Zaire strain, against which vaccines were developed in 2018 and 2019.
But "the lack of a vaccine does not mean the battle is lost," said Muyembe, who heads the state-run National Institute of Biomedical Research (INRB).
On his desk is a medal and photographs of him with dignitaries, as well as piles of letters from international partners and donors.
He pointed out that the DRC had overcome 15 Ebola outbreaks in the past using public health measures alone, long before vaccines and modern treatments were available.
Muyembe also said he was pleased to see African scientists, once reliant on foreign labs, play a key role in responding to outbreaks on the continent.
Still, health authorities in the DRC have faced criticism this time for delays in detecting the outbreak and in supporting overstretched frontline workers.
In recent weeks, fearing border closures, the government has insisted that the situation is under control.
Also lying on Muyembe's desk is an open file on mpox -- a reminder that Ebola is only one of several threats facing the DRC.
Muyembe believes the crises are linked. The country's exceptional biodiversity, combined with deforestation and climate change, has pushed communities deeper into the forests, and into closer contact with wildlife.
It makes the DRC "particularly vulnerable to epidemics of zoonotic diseases" that pass from animals to humans, like Ebola and mpox, he said.
- 'Greatest risk' -
After the initial 1976 outbreak, Ebola disappeared for nearly two decades, returning in 1995 in the western city of Kikwit, where it appeared as an outbreak of "red diarrhoea".
Drawing on his experience, Muyembe experimented by treating eight patients with blood transfusions from survivors.
Seven of them lived. The sample was small, but the concept laid the groundwork for a line of research that would eventually lead to the development of Ebanga, the first approved Ebola treatment, licensed in 2020.
Now a father of nine and grandfather to many, Muyembe reflected on that first mission as a young graduate freshly returned to the DRC.
Looking back, the virologist said he took "the greatest risk of my life" that day.
"I took part in identifying the virus and in treating the disease," the virologist said. "What more can one do in a lifetime?"
A.Gasser--BTB